Philippe Camus, M.D.

Dijon, France

Both apps are now back!

Back

The Drug-Induced Respiratory Disease Website and App

Adalimumab

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I - Interstitial/parenchymal lung disease

I.a

Pneumonitis (interstitial lung disease/ILD)
I.b

Pneumonitis (ILD), acute and/or severe (may cause ARDS)
I.c

Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
I.e

Organizing pneumonia pattern (an area or areas of consolidation on imaging)
I.g

Pulmonary fibrosis
I.n

ILD with a granulomatous component
I.x

Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)
I.aa

An area or areas of consolidation

XLI - Pulmonary edema - Acute lung injury - ARDS

XLI.e

ARDS - Acute lung injury

XLII - Pulmonary/alveolar./airway hemorrhage/bleeding

XLII.a

Alveolar hemorrhage (AH), diffuse AH (DAH)
XLII.d

Alveolar hemorrhage, diffuse (ANCA-positive/-related)

XLIII - Airway involvement

XLIII.a

Bronchospasm - Wheezing - Asthma

XLV - Pleural and/or pericardial involvement

XLV.d

Pleural/pericardial effusion, ANA positive (DI lupus)
XLV.m

Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

XLVIII - Neuromuscular / CNS involvement - Disordered breathing (during sleep)

XLVIII.j

Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis

XLIX - Systemic/Distant conditions, syndromes and reactions

XLIX.b

Antiphospholipid antibodies w/wo the APL syndrome
XLIX.d

Lupus - Lupus syndrome (see also Vd)
XLIX.e

Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)
XLIX.l

Myopathy-Myositis-Polymyositis (see also under Xba)
XLIX.m

Sarcoid-like granulomatosis (endo-/extrathoracic)
XLIX.u

Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

LI - Cardiovascular involvement / toxicity

LI.a

Left or biventricular dysfunction/failure
LI.s

Heart failure (biventricular, congestive)

LV - Imaging

LV.e

Imaging: Pulmonary opacities with a subpleural distribution
LV.k

Imaging: An area or areas of consolidation

LVIII - Pathology

LVIII.a

Path: NSIP-cellular pattern (see also Ia, Ib)
LVIII.d

Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
LVIII.f

Path: ILD with a granulomatous component (see also Im)

LIX - Infections & related conditions

LIX.a

Respiratory tract infection incl. pneumonia
LIX.b

Opportunistic pulmonary/systemic infections
LIX.c

Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)
LIX.e

Pneumocystis jiroveci pneumonia
LIX.f

Tuberculosis, miliary
LIX.g

Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo
LIX.y

Histoplamosis (reactivation)
LIX.z

Coccidioidomycosis